Lucas Souza Ferreira

Lucas Souza Ferreira

Auto-generated profile, based on publicly available information

Lucas Souza Ferreira

São Paulo State University (UNESP), School of Pharmaceutical Sciences, Department of Clinical Analysis, Araraquara, SP, Brazil

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2014 in Mycopathologia
Verified
Journal Article
Closed access
PDF file
AGAmanda Costa Gonçalves
Amanda Costa Gonçalves
DMDanielle Cardoso Geraldo Maia
Danielle Cardoso Geraldo Maia
LFLucas Souza Ferreira
Lucas Souza Ferreira
LMLuis Gustavo Silva Monnazzi
Luis Gustavo Silva Monnazzi
PAPâmela Alegranci
Pâmela Alegranci
ICIracilda Zeppone Carlos
Iracilda Zeppone Carlos

1 March 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JSJuliana Marques Senedese
Juliana Marques Senedese
FRFrancisco Rinaldi-Neto
Francisco Rinaldi-Neto
RFRicardo Andrade Furtado
Ricardo Andrade Furtado
HNHeloiza Diniz Nicollela
Heloiza Diniz Nicollela
LSLarissa Daniela Ribeiro de Souza
Larissa Daniela Ribeiro de Souza
JBJairo Bastos
Jairo Bastos
In Brazilian folk medicine, copaiba oleoresin is widely known for its therapeutic activity, especially its wound healing and anti-inflammatory actions. Considering the relationship between inflammatory processes and carcinogenesis, this paper reports on the Copaifera reticulata Ducke oleoresin (CRO) chemopreventive potential in the colon carcinogenesis model in rats. To understand the mechanisms involved in this effect, the anti-inflammatory activity of CRO and its major chemical constituent, the diterpene ent-polyalthic acid (PA), were evaluated on the production of nitric oxide (NO) and prostaglandin E2 (PGE2) in mouse macrophages. For the chemoprevention assessment, the effect of CRO administered by gavage was investigated on DNA damage, pre-neoplastic lesions and mitotic frequencies induced by the 1,2-dimethylhydrazine (DMH; intraperitoneal injection) carcinogen by comet, aberrant crypt focus (ACF) and long-term assays, respectively. CRO reduced DNA damage (average 31.5%) and pre-neoplastic lesions (average 64.5%) induced by DMH, which revealed that CRO has antigenotoxic and anticarcinogenic effects. In the long-term assay, treatment with CRO significantly decreased mitoses in the tumor tissue, which suggested that CRO influenced carcinogenesis progression. PA reduced NO levels induced by lipopolysaccharides in macrophages. However, this diterpene showed no effect on PGE2. Taken together, our results suggest that PA exerts anti-inflammatory action via the NO pathway. The CRO chemopreventive effect may be partly due to the anti-inflammatory property of its major chemical constituent, PA. Our findings indicate that CRO is a promising agent to suppress colon carcinogenesis.

20 November 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DFDEIVYS LEANDRO PORTUONDO FUENTES
DEIVYS LEANDRO PORTUONDO FUENTES
PDPaulo Roberto Dores-Silva
Paulo Roberto Dores-Silva
LFLucas Souza Ferreira
Lucas Souza Ferreira
COCarlos S. de Oliveira
Carlos S. de Oliveira
Damiana Téllez-MartínezDamiana Téllez-Martínez
Damiana Téllez-Martínez
ICIracilda Zeppone Carlos
Iracilda Zeppone Carlos
In recent years, research has focused on the immunoreactive components of the Sporothrix schenckii cell wall that can be relevant targets for preventive and therapeutic vaccines against sporotrichosis, an emergent worldwide mycosis. In a previous study, we identified a 47-kDa enolase as an immunodominant antigen in mice vaccinated with an adjuvanted mixture of S. schenckii cell wall proteins. Here, we sought to assess the protective potential of a Sporothrix spp. recombinant enolase (rSsEno) formulated with or without the adjuvant Montanide Pet-GelA (PGA) against the S. brasiliensis infection in mice. Mice that were immunized with rSsEno plus PGA showed increased antibody titters against rSsEno and increased median survival time when challenged with S. brasiliensis as compared with mice that had not been immunized or that were immunized with rSsEno alone. Immunization with rSsEno plus PGA induced a predominantly T-helper 1 cytokine pattern after in vitro stimulation of splenic cells with rSsEno: elevated levels of IFN-γ and IL-2, as well as of other cytokines involved in host defense against sporotrichosis, such as TNF-alpha, IL-6, and IL-4. Furthermore, we show for the first time the presence of enolase in the cell wall of both S. schenckii and S. brasiliensis. As a whole, our results suggest that enolase could be used as a potential antigenic target for vaccinal purposes against sporotrichosis.

20 July 2018 in Immunology
Verified
Journal Article
Closed access
PDF file
LFLucas Souza Ferreira
Lucas Souza Ferreira
DPDeivys Leandro Portuondo
Deivys Leandro Portuondo
MPMarisa Campos Polesi
Marisa Campos Polesi
ICIracilda Zeppone Carlos
Iracilda Zeppone Carlos

5 February 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
DFDEIVYS LEANDRO PORTUONDO FUENTES
DEIVYS LEANDRO PORTUONDO FUENTES
PDPaulo Roberto Dores-Silva
Paulo Roberto Dores-Silva
LFLucas Souza Ferreira
Lucas Souza Ferreira
Damiana Téllez-MartínezDamiana Téllez-Martínez
Damiana Téllez-Martínez
CMCaroline Maria Marcos
Caroline Maria Marcos
ICIracilda Zeppone Carlos
Iracilda Zeppone Carlos
In recent years, research has focused on the immunoreactive components of the S. schenckii cell wall that can be relevant targets for preventive and therapeutic vaccines against sporotrichosis, an emergent worldwide mycosis. In previous studies, we identified a 47-kDa enolase as an immunodominant antigen in mice vaccinated with purified fungal wall proteins and adjuvants. In this study, the immunolocalization of this immunogen in the cell wall of S. schenckii and S. brasiliensis is shown for the first time. In addition, a recombinant enolase of Sporothrix spp (rSsEno) was studied with the adjuvant Montanide Pet-GelA (PGA) as a vaccine candidate. The rSsEno was produced with high purity. In addition, mice immunized with rSsEno plus PGA showed increased antibody titers against enolase and increased median survival time comparedto nonimmunized or rSsEno-immunized mice. Enolase immunization induced a predominant T-helper-1 (Th1) cytokine pattern in splenic cells after in vitro stimulation with rSsEno. Elevated production of interferon-γ (IFN-γ) and interleukin-2 (IL-2) was observed with other cytokines involved in the innate immune defense, such as TNF-alpha, IL-6, and IL-4, which are necessary for antibody production. These results suggest that we should continue testing this antigen as a potential vaccine candidate against sporotrichosis.

31 October 2011 in Cytokine
Verified
Journal Article
Closed access
DMDjamile Cordeiro de Matos
Djamile Cordeiro de Matos
LRLivia Carolina de Abreu Ribeiro
Livia Carolina de Abreu Ribeiro
LFLucas Souza Ferreira
Lucas Souza Ferreira
MBMarcela Bassi
Marcela Bassi
MPMarisa Campos Polesi
Marisa Campos Polesi
ICIracilda Zeppone Carlos
Iracilda Zeppone Carlos